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BY-NC-ND license (http://creativecomAbstract Objective: Asthma sufferers exhibit high prevalence of anxiety/depression.
Elevated tumor-necrosis factor-alpha (TNF-a) levels in peripheral system and central nervous
system (CNS) are associated with anxiety/depression, whereas brain-derived neurotropic factor
(BDNF) has anti-depressant effects. An anti-asthma herbal medicine intervention ASHMI inhibits
peripheral TNF-a secretion in an animal model of asthma. We hypothesize that ASHMI and its
compounds may have modulatory effects on CNS TNF-a and BDNF production. We sought to
determine the effect of ASHMI and individual herb constituents on brain microglial cell TNF-a
production, and identify the active compounds that suppress TNF-a and increase BDNF.
Methods: BV-2 mousemicroglial cells were pre-treated with ASHMI or extracts ofGanoderma lu-
cidum (G. lucidum), Sophora flavescens Ait (S. flavescens), andGlycyrrhiza uralensis Fischer (G.
uralensis), the herbal constituents in ASHMI, or individual compounds isolated from G. uralensis
at different concentrations and then stimulated with LPS. TNF-a levels in culture supernatants
weremeasured by ELISA. The effect of active compounds onNFkB signaling pathway and on BDNF
production were determined by western blotting and ELISA, respectively.
Results: ASHMI produced dose-dependent inhibition of TNF-a secretion by cultured-mousemicro-
glia BV2 cells. Of the three herb extracts in ASHMI, only G. uralensis significantly and dose-
dependently inhibited TNF-a production. Among the 5 flavonoids isolated from G. uralensis,ntegrative Medicine for Allergies and Wellness, Division of Pediatric Allergy & Immunobiology, Icahn
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Glycyrrhiza uralensis flavonoids inhibit brain microglial cell TNF-a secretion 29isoliquiritigeninwas themost effective. Isoliquiritigenin suppression of TNF-a productionwas asso-
ciatedwith attenuationofp-NF-kBexpression, andwas accompaniedby increasedBDNF secretion.
Conclusion: ASHMI and its effective flavonoid, isoliquiritigenin, inhibited TNF-a production by LPS
stimulatedmicroglial cells and elevated BDNF levels, whichmay prove to have anti-CNS inflamma-
tory and anti-anxiety effects.
ª 2014 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).28e31
Introduction
Asthma, a chronic inflammatory airway disease, is the most
common respiratory disease in the United States, affecting
25 million people.1 Anxiety and depression are often asso-
ciated with poor asthma control and quality of life.2e7 The
prevalence of serious psychological distress among adults
with asthma (7.5%) is more than double that of the overall
US population (3.0%) and adults without asthma (2.6%).8
20% to 40% of adolescents with asthma experience signifi-
cant symptoms of anxiety.9 Current asthma treatment in-
volves the use of oral or inhaled corticosteroids and b2-
agonists and it has been suggested that these medications
may be responsible for the association of asthma with
depression and anxiety to some degree.10,11 Higher levels of
anxiety in asthmatic patients are positively associated with
high concentrations and long-term use of inhaled cortico-
steroids.12e14 These patients represent an important unmet
clinical need. Chronic treatment of mice with corticoste-
roids is used as a model for depression.15
Traditional Chinese medicine (TCM) has a long history for
the treatment of asthma, and is often used to simultaneously
treat comorbid conditions. ASHMI, an extract of 3 herbs:
Ganoderma lucidum, (G. lucidum), Sophora flavescentis (S.
flavescentis), and Glycyrrhiza uralensis (G. uralensis), de-
creases inflammation in amurine asthmamodel. It was found
to be safe and effective in clinical trials of adult asth-
matics16,17 and to inhibit macrophage TNF-a production in
vitro.18 It also was found to inhibit peripheral TNF-a pro-
duction in animalmodel of asthma.19G. uralensis is themost
common herb constituent both in TCM anti-asthma formulas
and mood-disorder formulas.20,21 We previously isolated 5
flavonoids from G. uralensis, and found that liquiritigenin
(LQG), isoliquiritigenin (ILQG), 7,40-dihydroxy flavones (7,40-
DHF) were more effective than liquiritin (LQ) and isoononin
(ISO) in suppression of inflammation-associated chemokines
and cytokines in vitro.22 G. uralensis and its flavonoids have
also been shown to have an anti-depressive effect in animal
models.23e25 However, precisemechanisms underlying these
effects have not been elucidated.
Asthma is a Th2 cell-driven disease. However,
pro-inflammatory cytokines such as TNF-a have been
implicated in many aspects of the airway pathology in
asthma and may play an important role in severe refractory
asthma.26 We previously showed that TNF-a increases
airway mucus production and mucus gene expression.27
TNF-a is a soluble, membrane-bound inflammatory
cytokine produced by monocytes, macrophages, and T-
cells. Although the mechanisms of development of
depression and anxiety comorbid with asthma are not fully
understood, inflammation contributes to development ofdepression. TNF-a plays an important role in the pe-
ripheral system and central nervous system (CNS) function.
TNF-a promotes neuroinflammatory cascades and also has
direct toxic effects on oligodendroglia that lead to neuronal
cell death and demyelination of oligiodentrites.29,32,33 TNF-
a is transcribed through, and activates, the Nuclear Factor
Kappa B (NF-kB) signaling system.34,35 NF-kB is normally
sequestered in the cytoplasm of nonstimulated cells and
consequently must be translocated into the nucleus to
function. The subcellular location of NF-kB is controlled by
a family of inhibitory proteins, IkBs, which bind NF-kB and
mask its nuclear localization signal, thereby preventing
nuclear uptake. In addition, increased depression has been
reported to be associated with reduced levels of brain-
derived neurotropic factor (BDNF), a growth factor pro-
duced by microglial cells.36e38 BDNF induces neurogenesis,
neuronal survival, and plasticity, thereby restoring the
neurodegenerative damage caused by pro-inflammatory
cytokines such as TNF-a. Although various studies have re-
ported the biological effects of ASHMI herbal constituents
and some of the isolated compounds,39e43 no studies of
ASHMI or compounds on CNS inflammation and BDNF pro-
duction have been previously reported.
Microglial cells are the resident phagocytes and innate
immune cells of the brain. Over the past few decades,
there has been an increased interest in microglia, as many
investigators have recognized the importance of this cell in
the homeostasis, as well as various pathologies, of the
central nervous system (CNS).44 Primary microglia cultures
are prevalent in neuroinflammatory research due to the
similarities in phenotype to in vivo cells. Microglia cultures
have been described as early as the 1930s; however, the use
of cultures to study microglia function did not occur until
after a method for obtaining and culturing large amounts of
microglia was developed and improved upon.44 BV-2
microglial cells derived from the cortex of mice early
after birth have been used extensively in research related
to neuroinflammatory neurodegenerative disorders.45,46 In
this study, we used BV-2 microglia cells and determined the
effects of ASHMI, its three herbal constituents and purified
flavonoids from G. uralensis on TNF-a secretion, NF-kB
signaling pathway expression, and BDNF production.Materials and methods
Herbal preparations and extractions and quality
control
Extracts of ASHMI and individual herbs in ASHMI were
manufactured by the Sino-Lion Pharmaceutical Company (a
30 S.P. Patil et al.Good Manufacturing Practice certified facility) in Weifang,
China as described previously.16
Five flavonoids from G. uralensis, were isolated as
before with modifications.22 Briefly, dried aqueous extract
of G. uralensis (200 g) was dissolved in distilled-water and
loaded onto a macroporous resin column (Amberlite XAD-7
HP), and sequentially eluted with water, 20% aqueous
ethanol, 70% aqueous ethanol, and 95% aqueous ethanol.
70% ethanol and 95% ethanol elutions were combined and
concentrated under reduced pressure, then subjected to
silica gel column chromatography, eluted with dichloro-
methane, dichloromethane-ethyl acetate step gradients.
Sephadex LH20 and recrystallization methods were used to
further purify the isolate compounds. By comparison of
TLC, HPLC, and liquidchromatographyemass spectrometry
(LC-MS; LCT-Premier micromass spectrometer, Waters
Corp., Milford, MA) spectra with standards in our labora-
tory,22 5 flavonoids from G. uralensis, LQ LQG, ILQG, 7,40-
DHF, ISO were identified and Fig. 1A showed the structures
of the compounds and Fig. 1B showed the presence of these
compounds in 3-dimensional HPLC fingerprints of G.Figure 1 Compounds isolated from G. uralensis. A. Chemical stru
HPLC-DAD fingerprint of G. uralensis with peaks identified correspuralensis. The operating parameters of the mass spec-
trometer setting are optimized as: Positive ion mode;
nebulizing gas at 50 L/h; Capillary and cone Voltage at
3200 V and 30 V respectively; Desolvation Temperature at
400 C; Source Temperature at 120 C; Desolvation gas:
500 L/h; High resolution mass acquisition Range set from
m/z 50 to1000.
BV-2 microglial cell culture
BV-2 microglial cells were a gift from Dr. Badie Behnam, City
of Hope Medical Center, CA. The cells were maintained in
Dulbecco’s Modification of Eagle’s Medium (DMEM) (Medi-
atech, Manassas, VA) supplemented with 5% Fetal Bovine
Serum (FBS) (Atlanta Biologics, Lawrenceville, GA), 1% L-
glutamine (200 mM) and 1% penicillin-streptomycin at tissue
culture condition. For the assay, the cells were scraped with
a cell scraper, and plated in a 24-well plate at a concentra-
tion of 1  105 cells/ml in DMEM media supplemented with
10% FBS, 1% L-glutamine and 1% penicillin-streptomycin. The
plate was incubated at tissue culture condition for 48 h forctures, names of 5 compounds isolated from G. uralensis. B. 3D-
onding to the compounds isolated.
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either treated with ASHMI, G. uralensis, G. lucidum, or S.
flavescentis (500e15 mg/mL). For initial screening of LQG,
ILQG, 7,40-DHF,LQ and ISO from G. uralensis, they were first
cultured at 25mg/ml, and LQG, ILQG, and 7,40-DHFwere then
cultured (0.7e25 mg/mL), 0.1% DMSO or media (DMEM
without FBS) alone and incubated at 37 C for 8 h. Afterwhich
500 ng/mL Lipopolysaccharides (LPS) (SigmaeAldrich, St.
Louis, MO) was added to all wells including a positive control
with LPS alone. Media alone wells without LPS or herb
treatment served as negative control (with and without
DMSO). The plates were further incubated at 37 C for 18 h
after which supernatants were collected and stored at
80 C for cytokine ELISA.
ELISA
TNF-a and BDNF in the supernatants from the assay proce-
dure were detected by using mouse TNF-a Mono/Mono ELISA
kit (BD, San Jose, CA) andBDNFEmax@ Immunol Assay System
(Promega, Madison, WI) as per the protocol in the kits.
MTT assay
A 200 ml aliquot of BV2 microglial cell suspension at a con-
centration of 1  105 cells/ml was plated in each well in 96-
well plate and similar concentration of herbs and LPS was
maintained as described above, except 4 h prior to the end of
18 h incubation, 20 ml of MTT [3-94,5-dimethythiazol-2-yl0-
2,5-diphenyltetrazolium bromide] solution (1 mg/mL) was
added toeachwell. After 18h theplatewas removed fromthe
incubator, the contents were aspirated from the wells and
200 ml of DMSO was added to each well. The plate was placed
on a shaker for 1 h in the dark and the OD value was read at
595 nm. OD value of LPS alone was considered as 100%.
Western blot analysis
2  106 cells in DMEM media supplemented with 10% FBS,
glutamine and 1% penicillin-streptomycin were seeded in
25 cm2 flasks and incubated at 37 C for 48 h. The cells
were incubated with either media (DMEM without FBS),
ILQG (6 mg/mL pre-treatment for 8 h) þ LPS (500 ng/mL) or
LPS alone for 30 and 60 min. Cytoplasmic extracts were
prepared after the incubation using Nuclear Extract kit
(Active Motif, Carlsbad, CA) and extracts were stored
at80 C. Proteins from the cell extract were denatured
with sample buffer (NuPage LDS sample buffer, Invitrogen)
containing 10% DTT and heating for 10 min at 70 C.
Further, the denatured proteins were separated by loading
10 mg/lane on 10% SDS-gels and transferred to nitrocellu-
lose membranes. Proteins were detected by anti-phospho-
IkBalpha, anti-IkBalpha and anti-phospho-IkB-alpha, anti-
IkB-alpha and anti-b-actin (loading control) mouse aniti-
bodies (Cell Signaling) as primary antibody, goat anti-
mouse IgG-HRP as the secondary antibody and ECL detec-
tion system (Thermo Scientific, Rockford, Illinois). The
results of western blot were quantitative image analyzed
by ICY software (Paris, France). IkB and p-IkB expression
were modulated with b-actin expression and compared
with non-stimulated, non-treated, medium alone group.Statistics
A Students t test was used to compare the values between
LPS stimulated and LPS stimulated plus treated culture
supernatants. A p value <0.05 was considered to be sta-
tistically significant. *p < 0.05, **p < 0.01 and ***p < 0.001
the different levels of significance. All statistical analyses
were performed using Sigma Stat software (Systat Software
Inc. Point Richmond, CA, USA).Results
ASHMI and herbal constituents suppress LPS-
stimulated microglia cell TNF-a secretion
ASHMI at 125e500 mg/ml produced statistically significant
(p < 0.01e0.001) and dose-dependent inhibition of TNF-a
secretion by LPS stimulated-mouse BV-2 microglial cells
when compared with LPS stimulated cells alone (Fig. 2A). IC
50 value was 116.8 mg/ml. Extracts of the individual ASHMI
herbs were tested for potential inhibition of TNF-a pro-
duction. Of these, G. uralensis produced significant and
concentration-dependent inhibition of TNF-a production at
all tested concentrations (15.6e500 mg/ml, p < 0.001,
Fig. 2A). IC50 value of G. uralensis was 16.9 mg/mL. The
other two herb constituents appeared to be less effective.
G. lucidum only at 500 mg/ml and S. flavescentis at 250 mg/
ml and 500 mg/ml showed significantly inhibition of TNF-a
production (p < 0.001). Since there was no concentration-
dependent data, IC50 value for G. lucidum and S. fla-
vescentis at these tested doses were not generated. The IC
50 value of G. uralensis was approximately 7 fold less than
ASHMI (IC50:116.8 mg/mL). Therefore G. uralensis might be
the major contributor to ASHMI suppression of TNF-a pro-
duction, although not the only one.
Cell viability was assessed by the MTT assay. Treatment
with ASHMI at concentration up to 500 mg/mL did not cause
any cell toxicity (Fig. 2B). There were no differences in cell
viabilityof S.flavescentis- andG. lucidum-treatedcells atany
tested concentrations. G. uralensis at 125 mg/mL, the con-
centration well above its IC50 concentration (Fig. 2B), did not
affect cell viability. Even at 500 mg/ml, there was only 25% of
reduction of cell viability. These data suggested that ASHMI
and three constituents have a high safety window.
ILQG from G. uralensis was a potent inhibitor of
LPS-stimulated BV2 microglia cell TNF-a production
Since G. uralensis potently inhibited TNF-a production by
BV-2 microglial cells, and a previous study showed that
G. uralensis and the flavonoids LQ and ILQ showed clinical
effects on depression-like behavioral changes,24 we un-
dertook identification of active flavonoids from G. uralensis
on the TNF-a production. All five purified flavonoids, which
were identified by comparison of TLC, HPLC, and LC-MC
profiles with standards in our laboratory22 as LQ, LQG,
ILQG, 7,40- DHF and ISO, at 25 mg/ml showed significant
inhibition of TNF-a production (Fig. 3, p < 0.001).
LQG, ILQG almost eliminated TNF-a production and 7,40-
DHF suppressed TNF-a production by approximately 70%.
Figure 2 ASHMI and its 3 individual herbs inhibited TNF-a production by an LPS stimulated-mouse BV-2 microglial cells. A. BV-2
microglial cells were pre-incubated with or without herbal extract for 8 h, followed by addition of LPS (500 ng/mL) and culture for
another 18 h. TNF-a production levels in cell culture supernatants were determined by ELISA. Data are expressed as mean  SEM of
three independent experiments. **p < 0.01, ***p < 0.001 verses (Vs) LPS/No ASHMI or herb group. B. Cell viability was evaluated by
MTT method versus stimulation alone group.
32 S.P. Patil et al.Because LQG, ILQG and 7,40-DHF were the most effective G.
uralensis flavonoids, we next conducted concentration-
dependent study focusing on these 3 flavonoids. IC50
values of LQG, ILQG 7,40-DHF were 4.86 mg/mL, 1.18 mg/mL
and 2.21 mg/mL respectively, ILQG being most effective
(Fig. 4A). ILQG at 6 mg/mL eliminated TNF-a production
without cytotoxicity (Fig. 4B). Therefore, treatment con-
centrations of 6 mg/mL of ILQG were considered as optimal
concentration for the following studies.
LQG from G. uralensis suppressed IkBa
phosphorylation
In this study, we determined protein expression of both
IkB and phosphorylation of IkB (pIkB) at different time
points following LPS stimulation with or without ILQG
pretreatment. p-IkB expression in the cytoplasmic ex-
tracts of BV-2 cells marked increased at 30 and 60 min
after stimulation with LPS (positive control) compared to
unstimulated cells (negative control) with optimal density
ratio 10:1, and 250:1, respectively. Pre-treatment of cells
with ILQG for 8 h resulted in reduction of p-IkB expressionat 30 and 60 min compared to that in LPS stimulated, but
untreated cells with optimal density ratio at 5:10 and
167:250 respectively. Consistently, ILQG pretreatment of
BV2 cells also reduced LPS stimulation-induced reduction
of IkB expression at 30 min capered to that in LPS stimu-
lated, but untreated cells with optimal density 0.8:0.6
(Fig. 5).ILQG from G. uralensis increased brain derived
neurotrophic factor (BDNF) secretion by LPS-
stimulated microglial cells
Microglial cells are also a source of BDNF secretion. How-
ever, this function can be suppressed by pro-inflammatory
cytokines. It was shown that BDNF levels were negatively
correlated with TNF-a level. Since ILQG potently inhibited
TNF-a production, we hypothesized that it may increase
BDNF production. We found significant and concentration-
dependent enhancement of BDNF production by LPS stim-
ulated microglial cells compared to untreated LPS stimu-
lated microglial cells (Fig. 6, p < 0.01e0.001).
Figure 3 TNF-a production by an LPS stimulated-mouse BV-2
microglial cells treated with ASHMI, G. uralensis, and 5 in-
dividual compounds isolated. BV-2 microglial cells were pre-
incubated with or without treatment for 8 h, followed by
addition of LPS (500 ng/mL) and culture for another 18 h. TNF-
a production levels in cell culture supernatants were deter-
mined by ELISA. Data are expressed as mean  SEM of three
independent experiments. ***p < 0.001 verses (Vs) LPS/No
treatment group.
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The prevalence of comorbid anxiety/depression symptoms
with asthma is high.9,47 The underlying mechanism for
existence of comorbid stress in asthmatics is not fully
understood but one theory is that stress induces upregu-
lation of proinflammatory cytokines such as IL-1, IL-6 and
TNF-a.29,33,48,49 TNF-a is predominantly produced by
monocytes and macrophages in the peripheral system.
Microglial cells are the major source of TNF-a and other
inflammatory cytokine production in the CNS. ASHMI, a
mixture of three herb extracts has been shown to reduce
airway hypersensitivity, eosinophil infiltration, goblet cell
formation, and lung Th2 cytokine levels in a murine model
of chronic asthma.50 Its safety and effectiveness have
been demonstrated in clinical trials. We previously showed
that ASHMI and organic extract fractions inhibited TNF-a
production by macrophages. In this study, we, for the first
time, show that ASHMI reduces the production of TNF-a
by LPS stimulated BV-2 mouse microglial cells in a dose-
dependent manner. Consequently, we tested the 3 indi-
vidual constituents in ASHMI and showed that G. ura-
lensis showed greater suppression of TNF-a than
G. lucidum and S. flavescentis. Concentrations which were
effective were not toxic to the cells. G. uralensis might be
responsible for ASHMI anti-TNF-a production by BV2
microglial cells.
G. uralensis, one of the most widely used Chinese
herbs, has a wide range of anti-inflammatory properties.
G. uralensis reduced circulating levels of TNF-a and IL-6,
while increasing IL-10 in LPS treated mice.51 G. uralensis
has been shown to decrease IL-8 in lung fibroblast cells.52
However, whether G. uralensis flavonoid compounds
inhibit TNF-a proinflmamtory cytokine production bymicroglial cells have not been previously reported. Of the
5 flavonoids isolated and identified from G. uralensis,
LQG, ILQG and 7,40-DHF were more potent than LQ and
ISO in suppression of TNF-a production (in a dose-
dependent manner), ILQG being most effect with IC50
1.8 mg/ml (Table 1).
Activation of the NF-kB pathway is central to the
expression of several pro-inflammatory cytokines
including TNF-a. In this study we focused on ILQG and
used optimal concentration to determine whether ILQG
inhibits NF-kB activation by measuring p-IkB and IkB
levels. Our data showed that pre-treatment of cells with
ILQG resulted in reduction of p-IkB levels and IkB degra-
dation. These results demonstrated that ILQG inhibited
NF-kB signaling pathway activation. The upstream mech-
anisms are not investigated in this study. Toll-like re-
ceptors (TLRs) play a critical role in recognition of
conserved pathogen-associated molecular patterns
derived from various microbial pathogens. TLR signaling
pathways trigger the activation of NF-kB mediated
through both MyD88- and TRIF-dependent pathways. LPS
(a TLR4 agonist) triggers both MyD88- and TRIF-dependent
pathways leading to the activation of NF-kB. Se-Jeong
Park et al.53,54 demonstrated that ILQG inhibits both
MyD88- and TRIF-dependent pathways and suppresses
homodimerization of toll-like receptor 4 by RAW264.7
macrophages. Whether ILQG exhibits same regulatory ef-
fects on the TLR-mediated NF-kB signaling pathways on
microglial cells requires further investigation in the future
studies.
In addition to contributing to neurodegenerative pro-
cess by inducing proinflammatory cytokines, microglia can
also induce the release of neurotrophic factors such as
BDNF. In our study, we observed that pre-treatment with
ILQG induced BDNF production in a concentration-
dependent manner in LPS-stimulated microglial cells.
BDNF and its receptor tyrosine kinase receptor B (TrkB)
play important roles in neurogenesis, cell survival,
regulation of synaptic plasticity and maintenance of
neurons throughout life.55,56 Postmortem studies found
that brains from depressed individuals contain reduced
levels of hippocampal and cortical BDNF.36,37 Direct infu-
sion of BDNF into the brains of animals has been shown to
produce an “antidepressant effect” in learned helpless-
ness and forced swim models of depression.38,57 Ours is
the first study to show that treatment of LPS stimulated
microglial cells with ILQG leads to beneficial production of
BDNF.
ILQG is a chalcone compound and found in various me-
dicinal herbs such as G. uralensis (licorice), Allium ascalo-
nicum, Sinofranchetia chinensis, Dalbergia odorifera, and
Glycine max L.58 It shows various pharmacological properties
including anti-cancer,59,60 anti-inflammation, neuro-
protective effects. We and others have reported ILQG
showed anti-peripheral inflammatory effects. For examples
ILQG inhibited LPS-stimulated pro-inflammatory cytokine(IL-
6, IL12, and TNF-a) productions in bone marrow-derived
dendritic cells61; LPS stimulated NO, IL-1 beta and IL-6
production by J774A.1 murine macrophages; LPS-induced
iNOS and COX-2 expression via the attenuation of NF-kB in
RAW 264.7 macrophages62; antigen-induced IL-4 and IL-5
production by memory Th2 cells in vitro63; and eotaxin-1
Figure 5 Regulatory effects of ILQG on p-IkBa, IkBa by LPS
stimulated-mouse BV-2 microglial cells. Macrophage RAW 264.7
cells were cultured in medium or treated with ILQG (6 mg/mL)
for 8 h, followed by stimulation of LPS (500 ng/mL) for 30 or
60 min. The expression of p-IkBa, IkBa and b-actin (as the
control) in whole cell extracts were evaluated by western-blot
analysis and quantitative ratio of p-IkBa, and IkBa expression
was performed by modulated with b-actin expression and
compared with medium alone group.
Figure 4 G. uralensis flavonoids LQG, ILQG 7,40-DHF inhibited TNF-a production by an LPS stimulated-mouse BV-2 microglial
cells. A. BV-2 microglial cells were pre-incubated with or without treatment for 8 h, followed by addition of LPS (500 ng/mL) and
culture for another 18 h. TNF-a production levels in cell culture supernatants were determined by ELISA. Data are expressed as
mean  SEM of three independent experiments. B. Cell viability was evaluated by MTT method versus stimulation alone group.
34 S.P. Patil et al.secretion by human fetal lung fibroblasts in vitro.22 ILQG also
was reported to have neuroprotective effect, for example,
ILQG inhibited amyloid b protein-induced neurotoxicity in
cultured rat cortical neurons by interfering with the in-
creases of [Ca(2þ)](i) and ROS64; protected against
glutamate-induced mitochondrial damage and hippocampal
neuronal cell death by limiting glutamate-induced oxidative
stress in vitro65; protects against methamphetamine-
induced neurotoxicity in mice.66 These previous studies
together with our new findings that ILQG suppressed TNF-a
and NF-kB activation, and increased in BDNF suggest that
ILQG may be a potential CNS anti-inflammatory compound,
and ASHMI may have a potential for asthma patients with
anxiety/depression comorbidities.
In conclusion, the prevalence of comorbid anxiety-
depression symptoms is high in asthmatics, and cortico-
steroids for asthma treatment may enhance anxiety-
depression. ASHMI has been shown to be safe and effec-
tive in patients with asthma with beneficial immunomo-
dualtory effects. In this study, we showed that ASHMI and
its herbal constituents G. uralensis flavonoids inhibit TNF-a
production by LPS stimulated microglial cells and elevate
BDNF levels. Further studies are required to fully elucidate
the mechanisms of action underlying ASHMI and its
Table 1 IC50 values of TNF-a Inhibition.
IC50 (95% CI)
ASHMI 116.8 (116.8e116.8)
Gan-Cao 16.96 (15.27e18.84)
Isoliquiritigenin 1.18 (1.10e1.27)
7,40 dihydroxyflavone 2.21 (1.89e2.58)
Liquiritigenin 4.86 (2.28e10.37)
Figure 6 BDNF secretion by LPS-stimulated microglial cells
treated with ILQG. BV-2 microglial cells were pre-incubated
with or without ILQG for 8 h, followed by addition of LPS
(500 ng/mL) and culture for another 18 h. BDNF production
levels in cell culture supernatants were determined by ELISA.
Data are expressed as mean  SEM of three independent
experiments.
Glycyrrhiza uralensis flavonoids inhibit brain microglial cell TNF-a secretion 35compounds CNS anti-inflammatory effects, and to investi-
gate clinical benefit in asthma patients with comorbid with
anxiety/depression.
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